Pavlakis, N., Sjoquist, K., Martin, A., Tsobanis, E., Yip, S., Kang, Y., Bang, Y., Alcindor, T., O'Callaghan, C., Burnell, M., Wong, K., Simes, R., et al (2016). Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial. Journal of Clinical Oncology, 34(23), 2728-2735. [More Inform...

STAT3 activation is associated with poor prognosis in human colorectal cancer (CRC). Our previous data demonstrated that regorafenib (Stivarga) is a pharmacological agonist of SH2 domain-containing phosphatase 1 (SHP-1) that enhances SHP-1 activity and induces apoptosis by targeting STAT3 signals in CRC. This study aimed to find a therapeutic drug that is more effective than regorafenib for CRC...

Currently there are three targeted therapies approved for the treatment of colorectal cancers. These include the epidermal growth factor receptor (EGFR) inhibitors, cetuximab and panitumumab, and the multikinase inhibitor regorafenib. It is important to understand and recognize the common presentations of cutaneous toxicity that result from these agents to effectively manage symptoms and preven...

AIM To evaluate the inhibitory effects of regorafenib (BAY 73-4506), a multikinase inhibitor, on corneal neovascularization (NV). METHODS Thirty adult male Sprague-Dawley rats weighing 250-300 g, were used. Corneal NV was induced by NaOH in the left eyes of each rat. Following the establishment of alkali burn, the animals were randomized into five groups according to topical treatment. Group ...

Metastatic colorectal cancer (mCRC) is associated with poor prognosis, and patients who have progressed on first- second-line chemotherapy limited treatment options. Regorafenib trifluridine-tipiracil are approved in third- or later-line settings, but survival benefit small. Immune checkpoint inhibitor (ICI) therapy nivolumab ± ipilimumab single-agent pembrolizumab microsatellite instability-hi...

INTRODUCTION Regorafenib was recently approved for patients with pretreated advanced colorectal cancer (aCRC), despite a moderate improvement of the patients' outcome, and significant toxicities. Based on previous studies showing that early fluorodeoxyglucose-positron emission tomography (FDG-PET)-based metabolic response assessment (MRA) might adequately select patients unlikely to benefit fro...